Prothena Co. PLC Insider Unloads $51,850 in Stock (PRTA)
Prothena Co. PLC (NASDAQ:PRTA) Insider Karin L. Walker sold 2,500 shares of the stock on the open market in a transaction dated Tuesday, August 12th. The shares were sold at an average price of $20.74, for a total transaction of $51,850.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Prothena Co. PLC (NASDAQ:PRTA) traded down 1.76% during mid-day trading on Wednesday, hitting $20.68. 416,405 shares of the company’s stock traded hands. Prothena Co. PLC has a 52 week low of $15.62 and a 52 week high of $49.24. The stock’s 50-day moving average is $20.11 and its 200-day moving average is $26.85. The company’s market cap is $566.1 million.
Prothena Co. PLC (NASDAQ:PRTA) last issued its quarterly earnings data on Monday, August 4th. The company reported $0.06 earnings per share (EPS) for the quarter. The company had revenue of $15.10 million for the quarter.
Several analysts have recently commented on the stock. Analysts at Zacks upgraded shares of Prothena Co. PLC from a “neutral” rating to an “outperform” rating in a research note on Tuesday, August 5th. They now have a $20.00 price target on the stock. Separately, analysts at Oppenheimer initiated coverage on shares of Prothena Co. PLC in a research note on Thursday, July 10th. They set an “outperform” rating and a $40.00 price target on the stock. Finally, analysts at Ladenburg Thalmann initiated coverage on shares of Prothena Co. PLC in a research note on Thursday, May 22nd. They set a “buy” rating and a $36.50 price target on the stock. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $37.44.
Prothena Corporation PLC is an Ireland-based, clinical-stage biotechnology company. The Company is engaged in discovering and developing monoclonal antibodies that are directed towards misfolded proteins or improper cell adhesion.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.